Suven Pharmaceuticals acquires 56% stake in NJ Bio for ₹53 cr

Suven Pharmaceuticals Limited (SPL), a Hyderabad-based CDMO, has acquired a 56% stake in NJ Bio, Inc. for approximately ₹53.51 crore, including a primary equity infusion of ₹12.45 crore. The acquisition, completed on December 20, 2024, aims to strengthen SPL's market position and capabilities. SPL specializes in NCE development and provides services to global pharmaceutical companies.